These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 22104159)
1. Positive response to trastuzumab in a case of HER2-overexpressing metastatic gastric cancer that presented as severe thrombocytopenia. Choi JH; Han HS; Lee HC; Lee OJ; Kim JT; Lim SN; Lee KH; Kim ST Onkologie; 2011; 34(11):621-4. PubMed ID: 22104159 [TBL] [Abstract][Full Text] [Related]
2. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648 [TBL] [Abstract][Full Text] [Related]
5. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. Al-Batran SE; Hozaeel W; Jäger E Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Barok M; Tanner M; Köninki K; Isola J Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915 [TBL] [Abstract][Full Text] [Related]
13. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. Bang YJ J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336 [TBL] [Abstract][Full Text] [Related]
14. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Lorenzen S; Lordick F Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336 [TBL] [Abstract][Full Text] [Related]
15. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M; Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914 [TBL] [Abstract][Full Text] [Related]
16. [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy]. Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y Gan To Kagaku Ryoho; 2012 Dec; 39(13):2553-5. PubMed ID: 23235178 [TBL] [Abstract][Full Text] [Related]
17. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806 [TBL] [Abstract][Full Text] [Related]
18. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986 [TBL] [Abstract][Full Text] [Related]